Close menu




February 21st, 2024 | 07:00 CET

Top news: BYD, Bayer and Globex Mining

  • Mining
  • Gold
  • Commodities
  • Electromobility
  • chemicals
Photo credits: pixabay.com

Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BYD CO. LTD H YC 1 | CNE100000296 , BAYER AG NA O.N. | DE000BAY0017 , GLOBEX MINING ENTPRS INC. | CA3799005093

Table of contents:


    Globex Mining: With strong newsflow

    After a significant price increase in December 2023, the Globex Mining share has been consolidating for several weeks. This may offer investors an exciting entry opportunity.

    The Canadian mining incubator has acquired numerous exploration projects or abandoned mines in recent years. The portfolio now comprises 240 projects ranging from precious metals such as gold and silver to rare earths and lithium, the raw material for electromobility. Globex does not carry out the costly exploration of the projects itself but makes the land available to other companies. In return, Globex receives cash, share options or subsequent royalty payments - the advantage is risk reduction and steady cash flow.

    The latest updates on numerous projects are positive and demonstrate Globex's broad diversification. Cartier Resources, for example, has announced that it has started a 25,000m drill program at Large Chimo Gold Mine and expects a gross metal payout of 3%. Brunswick Exploration has commenced a winter drill program on Globex's Lac Escale claims. The drilling will test a lithium-bearing vein swarm over a strike length of 2.8 km. There, Brunswicks had already outlined lithium-bearing pegmatite veins of considerable width and high grade.

    Manganese X Energy Corp. has signed a letter of intent with leading US battery technology company C4V. The next step could be an offtake agreement for the high-purity Battery Hill manganese project. C4V is currently testing a sample. Manganese X has filed a patent application for a groundbreaking manganese purification technology. The process is designed to process manganese carbonate into high-purity manganese sulphate monohydrate. Typical applications for manganese sulphate include the production of cathode material for lithium-ion batteries and fine chemicals. IAMGOLD mines the Fayolle open pit on the Globex license property and transports the ore to its mill in Westwood. Globex receives royalties from its 2% interest in Net Smelter. In December, this amounted to CAD 58,814.68.

    Those interested in learning more should register for today's virtual investor conference - IIF. Register here. Globex will present live at 2:30 pm CET.

    Globex will present at the 10th International Investment Forum: Register now

    Bayer: Dividend at a minimum and price target reduced

    The Bayer Board of Management is likely engaged in numerous talks with investors at the moment. However, the topics are likely to be much more negative than at Globex Mining. More bad news came from Leverkusen this week. Over the next three years, the Company will only pay the legally required minimum to shareholders. This means that a dividend of EUR 0.11 will be proposed at the Annual General Meeting. Bayer CEO Bill Anderson explains the move as follows: "Reducing our debt and increasing our flexibility are among our top priorities." It is no secret that Bayer needs money. The fines from legal disputes relating to glyphosate & Co. run into the billions and are never-ending. In addition, the Company urgently needs to invest in the pharmaceutical pipeline. Analysts are already speculating about the sale of its flagship product Aspirin and other over-the-counter medicines.

    After an initial fall in the share price, Bayer shares practically did not react to the news. Analysts at DZ Bank welcomed the dividend cut. After all, the debt reduction was necessary. Nevertheless, the target price was reduced from EUR 56 to EUR 47. The recommendation remains "Buy".

    BYD: Is the share buyback coming?

    BYD also wants to buy, specifically, its own shares. This was confirmed again over the weekend. The number of shares to be repurchased was not disclosed. BYD first raised the possibility of share buybacks in December 2023. At that time, a volume of USD 28.1 million was mentioned. The aim was to strengthen investor confidence and stabilize the Company's value. Although BYD is operating at full throttle, is in a neck-and-neck race with Tesla for the electromobility crown and is expanding worldwide, the share price is just over EUR 20 and thus at the level of the end of 2020. The Chinese company presents a new model or expands into a new market almost every week. Two new models are to be launched in Germany. For the first time, this will also include a hybrid model.


    For those who want to benefit from the commodities boom with reduced risk, the Globex Mining share is interesting. The Company is debt-free and its extensive portfolio guarantees a steady news flow. Unfortunately, Bayer's news flow is not positive. Will a split be the only option in the end? Updates on this are expected on March 5, 2024. BYD is undervalued, no question. However, the China risk and the ongoing price war for electric vehicles continue to deter investors.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Jens Castner on October 30th, 2026 | 05:45 CET

    When the stock market gets it wrong: Schott Pharma clears its name; Lahontan Gold and Instone are the next candidates

    • Speciality glass
    • Gold
    • Real estate
    • Chemicals
    • Silver
    • Expropriation
    • Health
    • Berlin
    • Misvaluations
    • Mining
    • Schott Pharma
    • Instone Real Estate
    • Lahontan Gold

    Markets are quick to judge, and often paint companies with a broad brush. When one company runs into difficulties, its competitors immediately come under suspicion too. Schott Pharma has already been through this and dispelled the doubts with strong figures. Its share price is recovering. For Lahontan Gold and Instone Real Estate, the recovery has yet to come. The Canadian gold explorer is being punished alongside the major producers, while the property developer is being grouped with Berlin's residential landlords. In both cases, the facts tell a different story. The share price upside is considerable.

    Read

    Commented by Jens Castner on October 29th, 2026 | 05:40 CET

    A Breakout in the Making? Desert Gold Ventures and Oklo following in Moderna's footsteps

    • Cancer therapy
    • Gold
    • Nuclear power
    • Biotech
    • Commodities
    • Data centres
    • Desert Gold
    • Moderna
    • Oklo
    • Analysts
    • Price targets
    • Milestones
    • Quarterly reports
    • Precious metal

    Created and published on behalf of Desert Gold Ventures.

    Moderna has already made the big leap. Yet the best trial data in the company's history sent the shares tumbling, because the success was already priced in. The situation is different for two stocks that have also reached crucial milestones but still attract little attention on the stock market. Desert Gold Ventures is on the verge of its first gold production in Mali. Nuclear power specialist Oklo has commissioned its first reactor, but still needs a little more time before its commercial breakthrough. Analysts' price targets for both shares are several times their current prices.

    Read

    Commented by Carsten Mainitz on October 29th, 2026 | 05:31 CET

    Gold, Tickets, Turnarounds! Why Stock Pickers Should Take a Closer Look at DRC Gold, CTS Eventim and Mutares Now

    • Stock Picking
    • Alpha
    • Investments
    • Gold
    • Exploration
    • Acquisition
    • Activist Investor

    The stock market is no petting zoo. Investors seeking returns have to go hunting themselves. Stock picking is the art of finding tomorrow's winners before the rest of the market wakes up. Under the leadership of industry veteran Klaus Eckhof, DRC Gold is working to take a stake in a gold project in the northeast of the Democratic Republic of the Congo. This could take the company to a whole new level. CTS Eventim is attracting renewed attention thanks to an activist investor. This could boost the share price. Mutares has many irons in the fire. Who is ahead?

    Read